View in EDS HTML Full Text PDF Full Text

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism.

Saved in:
Bibliographic Details
Title: Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism.
Authors: Vaquié AM; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Shah DR; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Brechbühl EES; Cancer Research-UK, Cambridge Research Institute, University of Cambridge, UK., McNicholas M; Department of Oncology, Early Cancer Institute, University of Cambridge, UK.; Cancer Research-UK, Children's Brain Tumour Centre of Excellence, University of Cambridge, UK., Xu Z; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Stockley JH; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Morcom L; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Gold Diaz D; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Girdler GC; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK., Seear RV; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, UK., Balmus G; Department of Clinical Neuroscience, UK Dementia Research Institute, University of Cambridge, UK.; Department of Molecular Neuroscience, Transylvanian Institute of Neuroscience, Cluj-Napoca, Romania., Ratan RR; Burke Neurological Institute and Brain and Mind Research Institute, Weill Cornell Medicine, White Plains, NY, USA., Bulstrode H; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK., Nathan JA; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, UK., Pathania M; Department of Oncology, Early Cancer Institute, University of Cambridge, UK.; Cancer Research-UK, Children's Brain Tumour Centre of Excellence, University of Cambridge, UK., Brindle KM; Cancer Research-UK, Cambridge Research Institute, University of Cambridge, UK., Rowitch DH; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.; Departments of Pediatrics and Neurosurgery, Cedars-Sinai Guerin Children's, Los Angeles, CA, USA.
Source: Molecular oncology [Mol Oncol] 2026 Feb; Vol. 20 (2), pp. 307-330. Date of Electronic Publication: 2025 Sep 21.
Publication Type: Journal Article
Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40975876
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Vaquié+AM%22">Vaquié AM</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Shah+DR%22">Shah DR</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Brechbühl+EES%22">Brechbühl EES</searchLink>; Cancer Research-UK, Cambridge Research Institute, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22McNicholas+M%22">McNicholas M</searchLink>; Department of Oncology, Early Cancer Institute, University of Cambridge, UK.; Cancer Research-UK, Children's Brain Tumour Centre of Excellence, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Xu+Z%22">Xu Z</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Stockley+JH%22">Stockley JH</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Morcom+L%22">Morcom L</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Gold+Diaz+D%22">Gold Diaz D</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Girdler+GC%22">Girdler GC</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Seear+RV%22">Seear RV</searchLink>; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Balmus+G%22">Balmus G</searchLink>; Department of Clinical Neuroscience, UK Dementia Research Institute, University of Cambridge, UK.; Department of Molecular Neuroscience, Transylvanian Institute of Neuroscience, Cluj-Napoca, Romania.<br /><searchLink fieldCode="AU" term="%22Ratan+RR%22">Ratan RR</searchLink>; Burke Neurological Institute and Brain and Mind Research Institute, Weill Cornell Medicine, White Plains, NY, USA.<br /><searchLink fieldCode="AU" term="%22Bulstrode+H%22">Bulstrode H</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Nathan+JA%22">Nathan JA</searchLink>; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Pathania+M%22">Pathania M</searchLink>; Department of Oncology, Early Cancer Institute, University of Cambridge, UK.; Cancer Research-UK, Children's Brain Tumour Centre of Excellence, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Brindle+KM%22">Brindle KM</searchLink>; Cancer Research-UK, Cambridge Research Institute, University of Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Rowitch+DH%22">Rowitch DH</searchLink>; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Paediatrics, Biomedical Campus, University of Cambridge, UK.; Departments of Pediatrics and Neurosurgery, Cedars-Sinai Guerin Children's, Los Angeles, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101308230%22">Molecular oncology</searchLink> [Mol Oncol] 2026 Feb; Vol. 20 (2), pp. 307-330. <i>Date of Electronic Publication: </i>2025 Sep 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons%2C+Inc%22">John Wiley & Sons, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101308230 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-0261 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215747891%22">15747891 </searchLink><i>NLM ISO Abbreviation: </i>Mol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40975876
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/1878-0261.70128
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 307
    Titles:
      – TitleFull: Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Vaquié AM
      – PersonEntity:
          Name:
            NameFull: Shah DR
      – PersonEntity:
          Name:
            NameFull: Brechbühl EES
      – PersonEntity:
          Name:
            NameFull: McNicholas M
      – PersonEntity:
          Name:
            NameFull: Xu Z
      – PersonEntity:
          Name:
            NameFull: Stockley JH
      – PersonEntity:
          Name:
            NameFull: Morcom L
      – PersonEntity:
          Name:
            NameFull: Gold Diaz D
      – PersonEntity:
          Name:
            NameFull: Girdler GC
      – PersonEntity:
          Name:
            NameFull: Seear RV
      – PersonEntity:
          Name:
            NameFull: Balmus G
      – PersonEntity:
          Name:
            NameFull: Ratan RR
      – PersonEntity:
          Name:
            NameFull: Bulstrode H
      – PersonEntity:
          Name:
            NameFull: Nathan JA
      – PersonEntity:
          Name:
            NameFull: Pathania M
      – PersonEntity:
          Name:
            NameFull: Brindle KM
      – PersonEntity:
          Name:
            NameFull: Rowitch DH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2026 Feb
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1878-0261
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Molecular oncology
              Type: main
ResultId 1